T-cell Based Immunotherapy for of Melanoma

Model scores of the 29,894 trials active now.

Model score 24% for any early termination, 8% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (851 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2015-01-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: tumormelanomaimmunotherapycellbrain
  Phrases that lowered it: to investigateinvestigate thecriteria patientschronicsingle
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1/2 (raises risk) · Design
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Drug's FAERS reports with a death: 27.8% (raises risk) · Drug's FDA history
• Responsible party: sponsor investigator (raises risk) · Design
• Maximum age: 70 (lowers risk) · Who can join
• Design: single group (raises risk) · Design
• Disease area, dermatology: Yes (raises risk) · Disease area
• Number of arms: not given (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 95.3% (raises risk) · Drug's FDA history
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Keywords listed: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma NCT01883323 · started 2013 · scored riskier than 99% of active trials completed
• L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma NCT04924413 · started 2021 · scored riskier than 46% of active trials terminated
• Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma NCT02278887 · started 2014 · scored riskier than 97% of active trials completed
• Adoptive Tumor-infiltrating Lymphocyte Transfer With Nivolumab for Melanoma NCT04165967 · started 2020 · scored riskier than 87% of active trials completed
• Vemurafenib and TIL Therapy for Metastatic Melanoma NCT02354690 · started 2014 · scored riskier than 94% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.